Barclays’s Roivant Sciences ROIV Stock Holding History

Barclays’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-97,300	Closed	-$1.47M	–	5609
2025 Q3	$1.47M	Buy	+97,300	New	+$1.2M	﹤0.01%	3113

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's ROIV Position: Q3 2026 in Review

Barclays increased its Roivant Sciences (ROIV) stake by 203% in Q3 2026, buying an estimated $31.5M and bringing the position to 1,294,355 shares worth $47.3M. The position accounts for 0.01% of the portfolio, ranked #804.

Barclays first reported a position in ROIV in Q1 2022 and has held it in 19 quarters since. 268 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

Barclays held 1,294,355 shares of Roivant Sciences worth $47.3M as of Q3 2026.
Barclays bought 867,670 Roivant Sciences shares in Q3 2026, an estimated $31.5M.
Roivant Sciences made up 0.01% of Barclays's portfolio in Q3 2026, its #804 holding.
Barclays first reported a position in Roivant Sciences in Q1 2022 and has held it in 19 quarters since.
268 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.